Category Archives: Ceritinib – Zykadia from Novartis

Effectivness of certain 2nd generation ALK inhibitors against specific ALK mutations

Four 2nd generation ALK inhibitors (Ceritinib, Alectinib, AP26113, and ASP3026) were tested in vitro against six known mutations of the ALK fusion gene. Generally, AP26113 was most effective and ASP3026 was least effective. In some cases one drug worked against … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Lung cancer, Research, Resistance to treatment | Leave a comment

Crizotinib followed by Ceritinib

A retrospective study of 73 patients who took Crizotinib followed by Ceritib  from 4 hospitals found positive results. The median progression free survival (PFS) on Crizotinib was 8.2 months. The median interval before starting Ceritinib was 25 days. The median … Continue reading

Posted in Ceritinib - Zykadia from Novartis, Crizotinib - Xalkori from Pfizer, Lung cancer, Research | Leave a comment

Video on Alectinib

Here is a video discussing Alectinib and comparing it with Crizotinib and Ceritinib. He also mentioned an upcoming trial that is being planned that would compare various sequences of the drugs. http://www.onclive.com/conference-coverage/thoracic-2014/Dr-Govindan-on-the-Potential-for-Alectinib

Posted in Brain metastases, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Research, Resistance to treatment | Leave a comment

Ceritinib effective on brain mets.

ALK-inhibitor naïve patients treated with ceritinib experienced an overall response rate (ORR) of 72.3% and a median progression-free survival (PFS) of 18.4 months. In ALK inhibitor treated patients, the ORR was 56.4% and the median PFS was 6.9 months. In … Continue reading

Posted in Brain metastases, Ceritinib - Zykadia from Novartis, Lung cancer, Research | Leave a comment

Video on ALK inhibitor efficacy

By Dr. Jack West http://www.onclive.com/peer-exchange/nsclc-needs/Efficacy-of-Next-Generation-ALK-Inhibitors

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Brain metastases, CEP-37440, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Entrectinib RXDX-101 by Ignyta, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, Side Effects, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

List of 8 ALK Inhibitors in trials

List of 8 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Pfizer – Crizotinib (2011 initial, 2013 final) Novartis – Ceritinib (2014 initial) FDA Breakthrough Status Chugai – Alectinib (approved in Japan in 2014) Ariad … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Entrectinib RXDX-101 by Ignyta, Lung cancer, Regulatory applications & approvals, Research, TSR-011 from Tesaro, X-396 from Xcovrery | Leave a comment

Collaboration between Novartis and Bristol Meyers Squibb

A collaboration between Novartis and Bristol-Myers Squibb (BMS) has resulted in the establishment of several clinical trials combining the PD-1 inhibitor nivolumab (Opdivo) with targeted therapies against ALK (Ceritinib), c-MET, and T790M for patients with non-small cell lung cancer (NSCLC). … Continue reading

Posted in Ceritinib - Zykadia from Novartis, Lung cancer, Research | Leave a comment

5-6 minute video by OncLive

The discussion is about Ceritinib by Novartis and AP26113 by Ariad. The main speakers are Dr. Shaw and Dr. Cambidge. https://m.youtube.com/watch?v=vRHm7XTE3fw Seems like it was recorded in May or June 2014.

Posted in AP26113 - Brigatinib from Ariad, Brain metastases, Ceritinib - Zykadia from Novartis, Lung cancer, Resistance to treatment, Side Effects | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in AP26113 - Brigatinib from Ariad, Brain metastases, Ceritinib - Zykadia from Novartis, CH542802 - Alectinib from Chugai - Roche, Crizotinib - Xalkori from Pfizer, Entrectinib RXDX-101 by Ignyta, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, Side Effects, TSR-011 from Tesaro, X-396 from Xcovrery | 1 Comment